Opella is Sanofi’s consumer healthcare business unit focusing on over-the-counter medicines, vitamins, minerals, and supplements and includes brands such as Allegra, Doliprane, and Dulcolax.

Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

Sanofi SAN-0.03%decrease; red down pointing triangle moved ahead with a plan to sell a controlling stake in its consumer-healthcare ... a business that is home to brands such as Allegra, Dulcolax ...

as well as brands including Mucosolvan cough syrup, Allegra allergy treatments and Buscopan pain relief. Sanofi, which said a year ago it was reviewing separation scenarios for its consumer health ...

Sanofi and CD&R are joining forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare ... With a portfolio of iconic brands, such as Allegra, Doliprane and Dulcolax ...

Sanofi and CD&R partner to ... to create a French-headquartered, global consumer healthcare champion. Opella is differentiated by the quality of its brand portfolio and its highly skilled and ...

Sanofi's consumer health unit, valued at $17.4 billion. Opella serves over 500M consumers globally with top brands like Allegra and Dulcolax. Sanofi SA SNY and private equity Clayton Dubilier ...

It also owns the antihistamine brand Allegra and the laxative Dulcolax. "Together, CD&R and Sanofi will support Opella’s growth strategy as a pure-play, global and fast-moving consumer ...